- Home
- CUE vs ZYXI Comparison
CUE vs ZYXI Comparison
Compare CUE & ZYXI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CUE
- ZYXI
- Stock Information
- Founded
- CUE 2014
- ZYXI 1996
- Country
- CUE United States
- ZYXI United States
- Employees
- CUE N/A
- ZYXI N/A
- Industry
- CUE Biotechnology: Pharmaceutical Preparations
- ZYXI Biotechnology: Electromedical & Electrotherapeutic Apparatus
- Sector
- CUE Health Care
- ZYXI Health Care
- Exchange
- CUE Nasdaq
- ZYXI Nasdaq
- Market Cap
- CUE 58.9M
- ZYXI 66.5M
- IPO Year
- CUE 2018
- ZYXI N/A
- Fundamental
- Price
- CUE $0.64
- ZYXI $1.99
- Analyst Decision
- CUE Strong Buy
- ZYXI Buy
- Analyst Count
- CUE 3
- ZYXI 3
- Target Price
- CUE $3.00
- ZYXI $6.00
- AVG Volume (30 Days)
- CUE 163.7K
- ZYXI 170.3K
- Earning Date
- CUE 05-12-2025
- ZYXI 07-24-2025
- Dividend Yield
- CUE N/A
- ZYXI N/A
- EPS Growth
- CUE N/A
- ZYXI N/A
- EPS
- CUE N/A
- ZYXI N/A
- Revenue
- CUE $7,991,000.00
- ZYXI $172,401,000.00
- Revenue This Year
- CUE N/A
- ZYXI N/A
- Revenue Next Year
- CUE $25.99
- ZYXI $19.55
- P/E Ratio
- CUE N/A
- ZYXI N/A
- Revenue Growth
- CUE 13.83
- ZYXI N/A
- 52 Week Low
- CUE $0.45
- ZYXI $1.66
- 52 Week High
- CUE $1.99
- ZYXI $10.62
- Technical
- Relative Strength Index (RSI)
- CUE 37.72
- ZYXI 45.50
- Support Level
- CUE $0.61
- ZYXI $2.20
- Resistance Level
- CUE $0.71
- ZYXI $2.66
- Average True Range (ATR)
- CUE 0.06
- ZYXI 0.19
- MACD
- CUE -0.00
- ZYXI 0.03
- Stochastic Oscillator
- CUE 17.84
- ZYXI 27.12
About CUE Cue Biopharma Inc.
Cue Biopharma Inc is a clinical-stage biopharmaceutical company. It is developing a novel and proprietary class of biologics drugs for the selective modulation of the human immune system to treat a broad range of cancers and autoimmune disorders. Its objective is to provide patients suffering from cancer and autoimmune diseases with dramatically improved therapeutic outcomes through the platform of biologic drug product candidates. The other products under pipeline are CUE-101 as a Monotherapy, CUE-101 + Pembrolizumab, CUE-102, CUE-103, and others.
About ZYXI Zynex Inc.
Zynex Inc is engaged in the manufacturing and marketing of medical devices. It operates through one primary business segment, Electrotherapy and Pain Management Products. The business activities of the company are carried out through its subsidiaries. The company designs, manufactures, and markets medical devices that treat chronic and acute pain, as well as activate and exercise muscles for rehabilitative purposes with electrical stimulation. The company operates business as one operating segment which includes two revenue types: Devices and Supplies. Its markets Zynex-manufactured products which include NexWave, NeuroMove, InWave E-Wave, and others.